Answers are grounded in this paper and cite their sources.
Comment evaluates statistical modeling and interpretation of real-world data in CGRP monoclonal antibody therapy for Japanese patients.
We read with interest the 12-month observational study by Imai et al. [1] regarding CGRP monoclonal antibodies (CGRP-mAbs) in Japanese patients. Although the study provides many valuable real-world data, we would like to raise three specific issues concerning the interpretation and statistical modeling of the data presented, about which more clarification is needed.
No takes yet. Share an insight, caveat, or question.
Ullah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: